Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

RCT (n=90) found a lower number of respiratory exacerbations over 6 months for those given azithromycin three times a week vs placebo (0.75 vs 1.62, rate ratio 0.45, 95%CI 0.26-0.78) Loose stools or diarrhoea were more common with azithromycin (23% vs 5%).

Source:

The Lancet Respiratory Medicine